Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Daniel S Chen"'
Autor:
Mario Perro, Vaios Karanikas, Marcin Kowanetz, Andreas Roller, Christian Klein, Marieke F. Fransen, Ines Matos, Stefano Sammicheli, Stanford Chen, Eva Sum, Pablo Umana, Vesna Pulko, Christian Jost, Regula B. Buser, Daniel S. Chen, Priti S. Hegde, Ferry Ossendorp, Sara Colombetti, Maud Léa Mayoux, Wei Xu, Anton Belousov, Karolin Rommel
Publikováno v:
Mayoux, M, Roller, A, Pulko, V, Sammicheli, S, Chen, S, Sum, E, Jost, C, Fransen, M F, Buser, R B, Kowanetz, M, Rommel, K, Matos, I, Colombetti, S, Belousov, A, Karanikas, V, Ossendorp, F, Hegde, P S, Chen, D S, Umana, P, Perro, M, Klein, C & Xu, W 2020, ' Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy ', Science Translational Medicine, vol. 12, no. 534, eaav7431 . https://doi.org/10.1126/scitranslmed.aav7431
Science Translational Medicine, 12(534):eaav7431. American Association for the Advancement of Science
Science Translational Medicine, 12(534). AMER ASSOC ADVANCEMENT SCIENCE
Science Translational Medicine, 12(534):eaav7431. American Association for the Advancement of Science
Science Translational Medicine, 12(534). AMER ASSOC ADVANCEMENT SCIENCE
PD-L1/PD-1 blocking antibodies have demonstrated therapeutic efficacy across a range of human cancers. Extending this benefit to a greater number of patients, however, will require a better understanding of how these therapies instigate anticancer im
Autor:
Elizabeth Budde, Catherine Diefenbach, Iris Sison, Ian W. Flinn, Philippe Armand, Genevive Hernandez, Ajay K. Gopal, Ibrahim Qazi, Loretta J. Nastoupil, Maya Leabman, Matthew J. Matasar, Won Seog Kim, Gareth P. Gregory, Bruce Keyt, Daniel S. Chen, Chan Yoon Y. Cheah, Ching-Fai Pang
Publikováno v:
Blood. 138:132-132
Introduction : IGM-2323 is the first engineered high-affinity, high-avidity bispecific IgM monoclonal antibody TCE to be tested in the clinic. It has 10 binding domains for CD20 and a single binding domain for CD3 and is designed to bind irreversibly
Autor:
Victor Cohen, Jamie E. Chaft, David S. Shames, Roel Funke, Zach Boyd, Peter Schmid, Vincent Leveque, Wei Zou, Simonetta Mocci, David R. Spigel, Hartmut Koeppen, Garret Hampton, Natasha Miley, Lukas C. Amler, Edward E. Kadel, Marcus Ballinger, Ira Mellman, Naiyer A. Rizvi, Geetha Shankar, Susan Flynn, Scott N. Gettinger, Dustin Smith, Fred R. Hirsch, Alan Sandler, Ignacio I. Wistuba, Marcin Kowanetz, Mark M. Kockx, Priti S. Hegde, Daniel S. Chen, Alexander I. Spira
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance Programmed death-ligand 1 (PD-L1) expression on tumor cells and tumor-infiltrating immune cells is regulated by distinct mechanisms and has nonredundant roles in regulating anticancer immunity, and PD-L1 on both cell types is important f
Autor:
Paul Hinton, Bruce Keyt, Daniel S. Chen, Madeline H. Tran, Chitra Saraiya, Ramesh Baliga, Stephen F. Carroll, Dean C. Ng, Marigold Manlusoc, Hai Lu, Yuan C. Cao, Sachi Rahman, Bing Shan, Marvin Peterson, Keyu Li, Avneesh Saini
Publikováno v:
Cancer Research. 80:5664-5664
We have developed a novel T cell engaging bispecific antibody platform that utilizes the high avidity of IgM antibodies, but further combines this with the high affinity and specificity of IgG antibodies. By grafting the affinity matured binding doma
Autor:
Steve Carroll, Marvin Peterson, Marigold Manlusoc, Bing Shan, Hai Lu, Sachi Rahman, Ramesh Baliga, Paul Hinton, Yuan Cao, Chitra Saraiya, Bruce Keyt, Daniel S. Chen, Dean Ng, Keyu Li, Madeline Tran, Avneesh Saini
Publikováno v:
Blood. 134:1574-1574
Unlike IgG antibodies, IgM antibodies are typically composed of a pentameric disc-like structure with 10 low affinity binding sites per molecule complexed with a joining chain (J-chain) protein. We have developed a novel T cell engaging bispecific an
Autor:
Kai H. Barck, Rafael Molina, Olivia Hwang, Ann De Mazière, David Kan, Adrian M. Jubb, Maike Schmidt, Louie Naumovski, Judith Klumperman, Tanya Smyczek, Mallika Singh, Daniel S. Chen, Ian Kasman, Priti S. Hegde, Qinghua Song, Rupal Desai, Jason H. Cheng, Mahrukh Huseni, Weilan Ye, Yin Zhang, Stacey Yeung, Anthony Lima, William F. Forrest, Richard A.D. Carano, Jeffrey Eastham-Anderson, Leisa Johnson, Michelle Nannini, Mark S. Dennis
Publikováno v:
Journal of Clinical Investigation. 123:3997-4009
Many oncology drugs are administered at their maximally tolerated dose without the knowledge of their optimal efficacious dose range. In this study, we describe a multifaceted approach that integrated preclinical and clinical data to identify the opt
Autor:
Fabien Gaire, Neeraj Sharma, Xian He, James W. Mier, Genevive Hernandez, David F. McDermott, Mario Sznol, Konstanty Korski, Jeffrey Wallin, Roel Funke, Galina Babitski, Daniel Waterkamp, Priti S. Hegde, Vincent Leveque, Daniel S. Chen, Hartmut Koeppen, James Ziai, Johanna C. Bendell, Marta Cañamero, Mitchell Denker, F. Stephen Hodi, Suzanne F. Jones
Publikováno v:
Nature Communications
Nature Communications, Vol 7, Iss 1, Pp 1-8 (2016)
Nature Communications, Vol 7, Iss 1, Pp 1-8 (2016)
Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination approaches are required to extend this benefit beyond a subset of patients. In preclinical models tumour-derived VEGF limits im
Autor:
Alessandra Castiglioni, Sanjeev Mariathasan, Ira Mellman, Edward E. Kadel, Kobe C. Yuen, Jillian L. Astarita, Suchit Jhunjhunwala, Rafael Cubas, Hartmut Koeppen, Yagai Yang, Shannon J. Turley, Yulei Wang, Richard Bourgon, Priti S. Hegde, Dorothee Nickles, Thomas Powles, Daniel S. Chen, Yasin Senbabaoglu
Publikováno v:
Cancer Research. 78:2979-2979
Checkpoint inhibitor blockade can result in robust and durable anti-tumor responses in various cancers, including metastatic urothelial cancer (mUC). However, these responses only occur in a subset of patients. Identifying determinants of response an
Autor:
Zachary Boyd, Rin Nakamura, Gregg Fine, Thomas Powles, Priti S. Hegde, Xiaodong Shen, Daniel P. Petrylak, Nicholas J. Vogelzang, Daniel S. Chen, Teiko Sumiyoshi, Christina Rabe, Mitchell Denker, Marcin Kowanetz, Siew-leng Melinda Teng, Qun J Wu, Yuanyuan Xiao, Yohann Loriot
Publikováno v:
Journal for Immunotherapy of Cancer
Treatment options for metastatic urothelial bladder cancer (UBC) are limited. Mutational complexity is known to be high in UBC and may correlate with increased immunogenicity. MPDL3280A, a human PD-L1 monoclonal antibody containing an engineered Fc-d
Autor:
Holbrook E Kohrt, Daniel S. Chen, Jonathan Hebb, Bryan Irving, Cariad Chester, Serena Chang, Idit Sagiv-Barfi, Gregg Fine, Ronald Levy, Marcin Kowanetz, Erin Waller, Debra K. Czerwinski, Amanda Rajapaksa
Publikováno v:
Cancer Research. 74:2941-2941
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Introduction: Tumor irradiation induces innate and adaptive immune responses which, rarely, lead to tumor regression at distant sites, the abscopal effect. We have previously demon